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Precis 
A single-arm Phase 2 trial demonstrated the efficacy and safety of blinatumomab, a bispecific T-cell 
engaging antibody construct, in patients with relapsed/refractory (r/r) Philadelphia chromosome–
  3 
positive (Ph+) acute lymphoblastic leukemia (ALL), a rare hematologic malignancy with limited 
treatment options. Using propensity score analysis, we demonstrate that efficacy outcomes (complete 
remission and overall survival) from the phase 2 trial with blinatumomab compare favorably with a 
cohort of similar patients with r/r Ph+ ALL treated with standard-of-care chemotherapy. 
 
  1 
  4 
Abstract 2 
Background 3 
A single-arm Phase 2 trial demonstrated the efficacy and safety of blinatumomab, a bispecific T-cell 4 
engaging antibody construct, in patients with relapsed/refractory (r/r) Philadelphia chromosome–5 
positive (Ph+) acute lymphoblastic leukemia (ALL), a rare hematologic malignancy with limited 6 
treatment options. We compared outcomes with blinatumomab to a historical control treated with 7 
standard of care (SOC). 8 
Methods 9 
The blinatumomab trial enrolled adult patients with Ph+ ALL who were r/r to at least one second-10 
generation tyrosine kinase inhibitor (N=45). We used propensity score analysis (PSA) to compare 11 
outcomes with blinatumomab to an external cohort of similar patients receiving SOC chemotherapy 12 
(N=55). PSA mitigated confounding variables between studies by adjusting for imbalances in age at 13 
diagnosis and start of treatment, sex, duration from diagnosis to most recent treatment, prior allogeneic 14 
hematopoietic stem cell transplantation, prior salvage therapy, and number of salvage therapies. 15 
Bayesian augmentation was applied to improve power to 80% using data from a Phase 3 blinatumomab 16 
study in Ph− r/r ALL.  17 
Results 18 
In the PSA, rate of complete remission or complete remission with partial hematologic recovery was 19 
36% for blinatumomab and 25% for SOC, resulting in an odds ratio of 1.54 (95% confidence interval [CI] 20 
0.61–3.89) or 1.70 (95% credible interval [CrI] 0.94–2.94) with Bayesian augmentation. Overall survival 21 
favored blinatumomab over SOC, with a hazard ratio of 0.81 (95% CI 0.57–1.14) or 0.77 (95% CrI 0.61–22 
0.96) with Bayesian augmentation.  23 
Conclusions 24 
These results further support blinatumomab as a treatment option for patients with Ph+ r/r ALL. 25 
 26 
Keywords: Philadelphia chromosome–positive acute lymphoblastic leukemia, blinatumomab, standard 27 
of care, propensity score analysis, remission, survival. 28 
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Introduction 36 
The development of BCR-ABL1 protein-specific tyrosine kinase inhibitors (TKI) has significantly improved 37 
outcomes in Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL).1-3 The 38 
standard of care (SOC) for de novo Ph+ ALL is induction with conventional or attenuated chemotherapy 39 
in combination with a TKI.2,3 Most patients achieve complete remission (CR) and proceed to allogeneic 40 
hematopoietic stem cell transplantation (alloHSCT).4 However, relapse can occur and is commonly 41 
associated with TKI-resistant mutations in the kinase domain of the BCR-ABL1 oncogene.5 There is no 42 
definitive evidence of sustained response or long-term survival with TKIs after relapse, with overall 43 
survival (OS) ranging from approximately 4 to 6 months.4,6,7  Compounding these challenges, Ph+ ALL is 44 
rare,8 limiting most clinical trials evaluating new treatments to single-arm studies.2,3 45 
Blinatumomab is a bispecific T-cell engaging antibody construct that binds simultaneously to 46 
CD3-positive cytotoxic T cells and CD19-positive B cells, allowing endogenous T cells to recognize and 47 
eliminate CD19-positive ALL blasts.9 Prior studies established the efficacy and safety of blinatumomab in 48 
Philadelphia chromosome–negative (Ph–) relapsed/refractory (r/r) ALL.10 Both Ph– and Ph+ B-precursor 49 
leukemic cells express CD19; therefore, blinatumomab was assessed in a single-arm Phase 2 study of 50 
patients with Ph+ r/r ALL who had received a second-generation TKI.11 Of the 45 patients enrolled, 36% 51 
achieved CR or CR with partial hematologic  recovery (CRh). Median OS was 7.1 months.  52 
To assess the relevance of the blinatumomab study results within the wider context of available 53 
treatment options, we compared treatment outcomes with those of an external control population. For 54 
rare diseases without a satisfactory SOC, regulatory agencies support the use of external controls as a 55 
method to demonstrate the efficacy of new treatments.12 A problem with this approach is the 56 
substantial variability among patients in the external control cohort. Propensity score analysis (PSA) 57 
provides a better balance between patients receiving the treatment of interest and the external control 58 
with respect to relevant baseline factors, enabling less biased comparison of outcomes.  59 
Here we report results of a PSA comparing efficacy data from the Phase 2 blinatumomab study 60 
with those of an external population—patients with Ph+ r/r B-precursor ALL who had received SOC after 61 
failure or resistance to treatment with second-generation TKIs.  62 
 63 
Methods 64 
External SOC 65 
The external SOC cohort was identified and developed from existing clinical databases at centers in Italy 66 
(Ospedale Papa Giovanni XXIII; Poli li i o “a t Orsola, Istituto “erag oli) and Spain (ICO-Hospital 67 
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Germans Trias i Pujol, Josep Carreras Research Institute). To align with the eligibility criteria of the Phase 68 
2 blinatumomab trial, patients with Ph+ r/r ALL included in the external SOC cohort were 8 years of 69 
age, r/r to at least one second-generation TKI (dasatinib, nilotinib, bosutinib, ponatinib), and had >5% 70 
bone marrow blasts. Patients were excluded if they had a history of malignancy other than ALL within 5 71 
years of initiating salavage SOC, central nervous system or extramedullary disease, or prior therapy with 72 
blinatumomab. There were no restrictions on qualifying salvage therapy.  73 
Data collection began in August 2017 and ended in January 2018. Fifty-five patients met all 74 
eligibility criteria and were included in the present analysis (see Supporting Information Figure s1). The 75 
baseline period started from the initial diagnosis of ALL and ended at the start of the qualifying salvage 76 
therapy, and data were collected from diagnosis until the date of death or last follow-up. Investigators 77 
received approval from an institutional review board or ethics committee of participating centers. 78 
 79 
Blinatumomab Ph+ ALL study 80 
The blinatumomab study was an open-label, single-arm, multicenter, Phase 2 clinical trial of 81 
blinatumomab in adults with Ph+ r/r ALL (ClinicalTrials.gov identifier NCT02000427). The study was 82 
conducted at 19 centers in Europe and the United States. Details of this study have been previously 83 
reported.11 Patients with Ph+ B-precursor ALL who were 8 years of age ere eligi le for e rollment 84 
provided they were r/r to at least one second-generation TKI, had >5% bone marrow blasts, and had an 85 
Eastern Cooperative Oncology Group performance status of 2. Exclusion criteria included alloHSCT 86 
within 12 weeks before the start of blinatumomab, active acute or chronic (Grade 2 to 4) graft-versus-87 
host disease, systemic treatment of graft-versus-host disease within 2 weeks of starting blinatumomab, 88 
history or presence of clinically relevant central nervous system pathology including central nervous 89 
system ALL, isolated extramedullary disease, and a history of malignancy other than ALL within 5 years. 90 
Blinatumomab was administered as a continuous intravenous infusion at a dose of 9 µg/day in Week 1 91 
of Cycle 1 and 28 µg/day thereafter. For each treatment cycle, blinatumomab was administered for 4 92 
weeks followed by 2 weeks off treatment. Patients who achieved a CR/CRh could receive up to three 93 
additional cycles of treatment. The baseline period for patients began in January 2014, and the study 94 
ended in May 2015. All patients provided informed consent and the study was approved by the 95 
institutional review boards of participating centers. 96 
 97 
Efficacy endpoints 98 
  7 
Efficacy endpoints for the PSA included OS and CR/CRh. For time-to-event analyses, patients were 99 
followed from the start date of blinatumomab or SOC therapy to the event or censored at the time they 100 
were lost to follow-up or alive. CR was defined as 5% bone marrow blasts, with platelets >100,000/μl, 101 
absolute neutrophil count >1000/μl and no evidence of extramedullary disease. CRh was defined as 5% 102 
bone marrow blasts, with platelets >50,000/μl and absolute neutrophil count >500/μl. Response was 103 
determined within the first two treatment cycles in the blinatumomab study (∼70 days) but varied for 104 
the SOC cohort depending on the treatment (median time to response was 48 days).  105 
 106 
 Propensity score analysis 107 
PSA was planned and pre-specified prior to conducting endpoint analyses. PSA creates a balance 108 
between the blinatumomab and external SOC cohorts with respect to available baseline covariates that 109 
determine both the propensity for a patient to be treated (with blinatumomab) a d a patie t s 110 
prognosis.13-15 Baseline covariates included age at diagnosis and treatment, sex, time from diagnosis to 111 
most recent treatment (months), prior alloHSCT (yes, no), prior salvage therapy (yes, no) and number of 112 
prior salvage therapies (0, 1, 2, 3 and 4). An estimated propensity score (i.e., the predicted probability 113 
of participating in the blinatumomab Phase 2 trial) was assigned to each patient based on the selected 114 
covariates. The balance of covariates between patients in the blinatumomab trial and patients in the 115 
external cohort was determined by calculation of standardized differences in each covariate before and 116 
after propensity score adjustment and box plot overlap in propensity scores. 117 
In the estimation of treatment effects, propensity scores were used to adjust for differences 118 
between patients in the blinatumomab and external SOC cohorts using inverse probability of treatment 119 
weighting (IPTW) methods.16 The objective was to estimate the average treatment effect (ATE) from 120 
moving the entire population from untreated to treated.17 Sensitivity analyses explored use of stabilized 121 
IPTW (sIPTW), which accounts for potential instability caused by very large weights,18 and average 122 
treatment effect of treated weights (ATT).19 Covariates with a standardized difference of >0.20 after 123 
IPTW adjustment were added to statistical models as a covariate. 124 
CR/CRh rates were analyzed using a logistic regression model with a single-treatment indicator 125 
covariate and propensity score–based weights to adjust for differences between blinatumomab and 126 
external SOC cohorts. The odel s oeffi ie t for treatment effect was used to obtain an odds ratio, and 127 
a robust variance estimation (applied with a generalized estimating equation) was used to construct 128 
95% confidence intervals (CI) to evaluate the probability of CR/CRh. Similarly, OS was analyzed via a Cox 129 
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proportional hazards model with a single-treatment indicator covariate and using propensity score–130 
based IPTW or sIPTW weights to adjust for differences.  131 
Given the small sample sizes, the PSA had a statistical power of 65% to detect an assumed 132 
hazard ratio of 0.75 favoring blinatumomab treatment. To increase power, Bayesian augmentation was 133 
applied to endpoint analyses using distributions of OS and the odds ratio of CR/CRh from the Phase 3 134 
trial of blinatumomab versus SOC in patients with Ph– r/r B-cell precursor ALL.10 For Bayesian models, 135 
point estimates and 95% credible intervals (CrI) were estimated using summary statistics and the 136 
relative highest posterior density interval of the posterior distributions for model parameters of interest. 137 
Bayesian models used enough borrowing  from the Phase 3 trial to achieve a power of 80%. Potential 138 
bias was assessed by completing sensitivity analyses with pre-specified lower levels of borrowing  (i.e. 139 
power levels of 70% and 75%). Statistical programming was conducted in SAS 9.4 (SAS Institute, Cary, 140 
NC). 141 
 142 
Results 143 
Patient characteristics are presented in Table 1. All but 1 patient in each of the cohorts were enrolled 144 
based on Ph+ r/r ALL to a second-generation TKI. One patient in the external SOC cohort was intolerant 145 
to a second-generation TKI and had failed or was intolerant to imatinib, while 1 patient in the 146 
blinatumomab cohort was resistant to imatinib but had not received a second-generation TKI (protocol 147 
deviation). 148 
The study populations were generally similar with respect to gender and age, but differences 149 
were noted for geographic region and prior treatments. The proportion of patients with no prior salvage 150 
therapy was higher in the blinatumomab cohort (13% vs. 31%), as was prior treat e t ith  TKIs (16% 151 
vs. 38%) and prior alloHSCT (33% vs. 44%). Dasatinib was the most common prior TKI in both cohorts 152 
(89% vs. 87%). Prior treatment with imatinib was more common in the external SOC cohort (87% vs. 153 
56%), while prior treatment with ponatinib was more common in the blinatumomab cohort (13% vs. 154 
51%). 155 
Qualifying salvage therapies in the external SOC cohort included chemotherapy (22%), 156 
chemotherapy plus TKI (29%), and TKI alone (31%) (see Supporting Information Table s1). Common 157 
chemotherapy agents included mercaptopurine, vincristine, cytarabine, cyclophosphamide, and 158 
mitoxantrone. Generally, chemotherapy included combination regimens, such as HAM (high-dose 159 
cytarabine and mitoxantrone), MEC (mitoxantrone, etoposide and cytarabine), and hyper-CVAD 160 
(cyclophosphamide, vincristine, doxorubicin, and dexamethasone). Other treatments (18%) included 161 
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aurora kinase inhibitor, bortezomib, and donor leukocyte infusion, used alone or as part of a 162 
combination chemotherapy regimen, and salvage alloHSCT. Use of corticosteroids was common. 163 
Fifteen patients (27%) in the external SOC cohort achieved CR/CRh with their qualifying salvage therapy, 164 
with 14 (25%) achieving a CR and 1 (2%) achieving a CRh (Table 2). Of 51 patients for whom OS data 165 
were available, median OS was 6.0 (95% CI 4.4–9.2) months (Supporting Information Fig s2).  166 
The primary analysis of the blinatumomab study has been previously reported.11 The CR/CRh 167 
rate was 36% after two cycles, with 14 patients (31%) achieving a CR and 2 patients (4%) achieving a 168 
CRh. Median OS was 7.1 months (95% CI 5.6–not estimable).  169 
 170 
Propensity score analysis 171 
All propensity scores for the external SOC control were contained within the 95% range of the 172 
propensity scores for blinatumomab, indicating that most patients in the external SOC would have been 173 
eligible to receive blinatumomab treatment (Supporting Information Fig s3). Two covariates had >0.20 174 
standardized difference between the cohorts: prior alloHSCT and no prior salvage therapy (Supporting 175 
Information Table s2). After adjustment with IPTW, the standardized difference became 0 for no prior 176 
salvage therapy and was reduced from –0.33 to –0.23 for prior alloHSCT. Because the difference 177 
remained >0.20, the propensity score models incorporated IPTW-ATE adjustment with prior alloHSCT as 178 
a covariate. 179 
The Bayesian-augmented (80% power) odds ratio estimate for CR/CRh was 1.70 (95% CrI 0.94–180 
2.94), favoring blinatumomab over the external SOC (Table 3). Corresponding CR/CRh rate estimates for 181 
the blinatumomab and the external SOC cohorts were 36% (95% CrI 28%–46%) and 25% (95% CrI 17%–182 
34%), respectively. The non-Bayesian (65% power) odds ratio was 1.54 (95% CI 0.61–3.89).  183 
The Bayesian-augmented (80% power) hazard ratio comparing OS of blinatumomab with the 184 
external SOC was 0.77 (95% CrI 0.61–0.96), suggesting a statistically significant 23% reduction in the risk 185 
of death associated with blinatumomab compared with external SOC.  The non-Bayesian (65% power) 186 
hazard ratio was 0.81 (95% CI 0.57–1.14) (Table 4; Fig 1).  187 
Sensitivity analyses of less borrowing for Bayesian augmentation were consistent with these 188 
analyses (see Supporting Information Table s3 [CR/CRh] and Fig s4 [OS]), as were ATT sensitivity analyses 189 
(Supporting Information Table s4 [CR/CRh] and Table s5, Figs s4 and s5 [OS]) and sIPTW analyses 190 
(Supporting Information Fig s6 [OS]). 191 
 192 
Discussion 193 
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In the single-arm Phase 2 blinatumomab trial, adult patients with Ph+ r/r ALL receiving blinatumomab 194 
achieved a CR/CRh rate of 36%, with a median OS of 7.1 months.11  These results suggested an 195 
improvement in treatment outcomes with blinatumomab compared with historical studies but were 196 
limited by the single-arm trial design.4,6,7 In the current analysis, PSA places these efficacy results into 197 
the context of available treatment options. By aligning the eligibility criteria of the external SOC with 198 
that of the blinatumomab study, a similar patient population was selected for comparison. Both patient 199 
populations were heavily pretreated and balanced for most baseline covariates. In the external SOC, the 200 
CR/CRh rate was 26% and median OS was 6.0 months, consistent with historical Ph+ ALL studies.4,6,7   201 
PSA adjusted for imbalances in prognostic covariates and Bayesian augmentation was applied to 202 
improve statistical power. Bayesian-augmented PSA demonstrated a 70% increase in the odds of 203 
achieving remission with blinatumomab compared with external SOC, a numerical benefit that did not 204 
reach statistical significance. The Bayesian-augmented analysis of OS showed a statistically significant 205 
23% decrease in the hazard of death with blinatumomab treatment compared with SOC, and sensitivity 206 
analyses were consistent with these findings. For future salvage treatment strategies, these 207 
observations are of great importance, particularly among patients for whom an alloHSCT is planned only 208 
in second remission.20,21 209 
Although safety data for the external SOC were not available for comparison, treatment toxicity 210 
is a relevant concern. During the Phase 2 blinatumomab study, all patients experienced at least one 211 
treatment-emergent adverse event (AE) and 82% experienced a Grade  AE, but these were generally 212 
manageable as only 7% of patients discontinued treatment due to an AE.11 The most common Grade  213 
AEs included febrile neutropenia (27%), thrombocytopenia (22%) and anemia (16%). One fatal AE (septic 214 
shock) was considered treatment-related by the investigator. Overall, blinatumomab was tolerable with 215 
manageable AEs.  216 
Given the benefit-to-risk profile of blinatumomab in the Phase 2 trial and across clinical trials in 217 
ALL,10,11 future studies are looking to pair blinatumomab with TKIs, as the combination may provide 218 
additional benefit to patients with Ph+ ALL.22 There is also evidence in Ph– ALL to support the use of 219 
blinatumomab at earlier stages of treatment, including patients who have achieved CR/CRh with 220 
induction therapy but still have minimal residual disease (MRD).10,23 In the Phase 2 trial, 18/45 patients 221 
with Ph+ r/r ALL who received blinatumomab achieved an MRD response, with the median OS not 222 
reached for MRD responders compared with 3.9 months for MRD nonresponders.11  MRD response data 223 
were not available for all patients in the external SOC cohort, so a comparison was not possible.  224 
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PSA has become an established method to support development of novel treatments for rare 225 
malignancies.12,24 However, there are limitations. While the PSA mitigates the impact of known 226 
confounders and bias, it is not a replacement for randomization. In the propensity score model, one can 227 
only consider known covariates that are measured in both studies. The use of PSA cannot address 228 
imbalances in unmeasured/unknown covariates or post-baseline variables.  We did not have data on 229 
ECOG performance status or kinase domain mutations for the external SOC cohort, and post-treatment 230 
alloHSCT was more frequent with blinatumomab than with external SOC (15% vs. 9%). Other limitations 231 
include the small sample size of the cohorts, response assessment by centralized (blinatumomab study) 232 
versus investigator review (external SOC) and geographic and chronologic differences between the study 233 
cohorts. The blinatumomab study was conducted in the United States and Europe, while the external 234 
SOC included patients enrolled at centers in Italy and Spain with some patients treated 9 years before 235 
the initiation of the blinatumomab study. Although differences in clinical practice could be present 236 
between these cohorts (eg, the use of newer TKIs such as ponatinib and nilotinib), general practice 237 
patterns for ALL over time and between regions was not dramatically different. Treatment with TKIs and 238 
chemotherapies were standard treatment options. Selecting for specific qualifying salvage therapies 239 
may have introduced additional bias. 240 
In conclusion, the results from the PSA reported here suggest that blinatumomab improves 241 
treatment outcomes in patients with Ph+ r/r ALL compared with external SOC. These data further 242 
support blinatumomab as a treatment option for patients with Ph+ r/r ALL.243 
  12 
References 
1. Brissot E, Labopin M, Beckers MM, et al. Tyrosine kinase inhibitors improve long-term outcome 
of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia 
chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100(3):392-399. 
2. Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C. Acute lymphoblastic leukaemia 
in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann 
Oncol. 2016;27(suppl 5):v69-v82. 
3. NCCN. NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia Version 
I.2018. 2018; https://www.nccn.org/. Accessed September 20, 2018. 
4. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute 
lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944-950. 
5. Zabriskie MS, Eide CA, Tantravahi SK, et al. BCR-ABL1 compound mutations combining key 
kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive 
leukemia. Cancer Cell. 2014;26(3):428-442. 
6. Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic 
leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA 
Study Group. Haematologica. 2010;95(4):589-596. 
7. Spyridonidis A, Labopin M, Schmid C, et al. Outcomes and prognostic factors of adults with acute 
lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An 
analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia. 2012;26(6):1211-
1217. 
8. Faderl S, O'Brien S, Pui CH, et al. Adult acute lymphoblastic leukemia: concepts and strategies. 
Cancer. 2010;116(5):1165-1176. 
9. Wolach O, Stone RM. Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, 
Precursor B-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015;21(19):4262-4269. 
10. Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus Chemotherapy for Advanced 
Acute Lymphoblastic Leukemia. N Engl J Med. 2017;376(9):836-847. 
  13 
11. Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in 
adult patients with relapsed/refractory Philadelphia chromosome-positive b-precursor acute 
lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-
arm, multicenter study. J Clin Oncol. 2017;35(16):1795-1802. 
12. Simon R, Blumenthal GM, Rothenberg ML, et al. The role of nonrandomized trials in the 
evaluation of oncology drugs. Clin Pharmacol Ther. 2015;97(5):502-507. 
13. Levenson MS, Yue LQ. Regulatory issues of propensity score methodology application to drug 
and device safety studies. J Biopharm Stat. 2013;23(1):110-121. 
14. Yue LQ. Statistical and regulatory issues with the application of propensity score analysis to 
nonrandomized medical device clinical studies. J Biopharm Stat. 2007;17(1):1-13. 
15. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment 
to a non-randomized control group. Stat Med. 1998;17(19):2265-2281. 
16. D'Agostino RB, Jr., D'Agostino RB, Sr. Estimating treatment effects using observational data. 
JAMA. 2007;297(3):314-316. 
17. Imbens GW. Nonparametric Estimation of Average Treatment Effects Under Exogeneity: A 
Review. The Review of Economics and Statistics. 2004;86(1):4-29. 
18. Cole SR, Hernan MA. Adjusted survival curves with inverse probability weights. Comput Methods 
Programs Biomed. 2004;75(1):45-49. 
19. Hirano K, Imbens G, Ridder G. Efficient Estimation of Average Treatment Effects Using the 
Estimated Propensity Score. Econometrica. 2003;71(4):1161-1189. 
20. Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line 
therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a 
single-centre, phase 2 study. Lancet Oncol. 2015;16(15):1547-1555. 
21. Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of 
patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus 
chemotherapy. Blood. 2013;122(7):1214-1221. 
  14 
22. Assi R, Kantarjian H, Short NJ, et al. Safety and Efficacy of Blinatumomab in Combination With a 
Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive 
Leukemia. Clin Lymphoma Myeloma Leuk. 2017;17(12):897-901. 
23. Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults 
with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522-1531. 
24. Gokbuget N, Kelsh M, Chia V, et al. Blinatumomab vs historical standard therapy of adult 
relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J. 2016;6(9):e473. 
  15 
Table 1. Baseline characteristics 
 
External SOC 
(N = 55) 
Blinatumomab study 
(N = 45) 
Median age,* years (range) 53 (20–82) 55 (23–78) 
Age category,* n (%)   
18–34 years 9 (16) 5 (11) 
35–54 years 22 (40) 17 (38) 
55 years 24 (44) 23 (51) 
Sex   
Male 28 (51) 24 (53) 
Female 27 (49) 21 (47) 
Geographic region/country   
United States 0 11 (24) 
European Union 55 (100)  34 (76) 
Lines of prior salvage treatment, n (%)   
0 7 (13) 14 (31) 
1 31 (56) 12 (27) 
2 17 (31) 19 (42) 
No. of prior TKI treatments   
1 6 (11) 7 (16) 
2 41 (75) 21 (47) 
 8 (16) 17 (38) 
Prior TKIs,* n (%)   
Imatinib 48 (87) 25 (56)  
Dasatinib 49 (89) 39 (87) 
Ponatinib 7 (13) 23 (51) 
Nilotinib 10 (18) 16 (36) 
Multiple TKIs 49 (89) 38 (84) 
Prior alloHSCT, n (%)   
Yes 18 (33) 20 (44) 
No 37 (67) 25 (56) 
alloHSCT, allogeneic hematopoietic stem cell transplantation; SOC, standard of care; TKI, tyrosine kinase 
inhibitor. 
*Prior to start of qualifying salvage therapy for the external SOC cohort. 
Spain (n = 14), Italy (n = 41). 
One patient had ALL resistant to imatinib and was never exposed to a second-generation or later TKI.
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Table 2. Treatment outcomes 
 
External SOC  
(N = 55) 
Blinatumomab study 
(N = 45) 
Response to treatment,* n (%)  
Overall complete remission 15 (27) 16 (36) 
Complete remission 14 (25) 14 (31) 
Complete remission with partial hematologic recovery 1 (2) 2 (4) 
Complete remission with incomplete hematologic recovery 1 (2) 2 (4) 
Blast free hypoplastic or aplastic bone marrow NA 3 (7) 
Partial remission 1 (2) 2 (4) 
No response NA 12 (27) 
Refractory/progressive disease/early death 28 (51) 4 (9) 
Unknown/missing 10 (17) 6 (13) 
Proceeded to alloHSCT, n (%) 8 (15) 4 (9) 
Median overall survival, months (95% CI) 6.0 (4.4–9. )  7.1 (5.6–NE) 
CI, confidence interval; alloHSCT, allogeneic hematopoietic stem cell transplantation; NA, not available; NE, not estimable; SOC, standard of care. 
*Response within first two cycles of treatment for blinatumomab study. 
Overall survival data available for 51 patients (4 missing treatment start or last follow-up date).  
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Table 3. Summary of CR/CRh analysis with and without Bayesian augmentation and adjusted by inverse 
probability of treatment weighting (IPTW) – average treatment effect (ATE) 
Endpoint 
External SOC  
(N = 55) 
Blinatumomab study 
(N = 45) 
Non-Bayesian (65% power) OR 1.54 (95% CI 0.61–3.89); P = 0.26 
CR/CRh (95% CI) 26% (16%–40%) 36% (22%–52%) 
Bayesian augmentation (80% power) OR 1.70 (95% CrI 0.94–2.94); P = 0.076 
CR/CRh (95% CrI) 25% (17%–34%) 36% (28%–46%) 
CI, confidence interval; CR, complete remission; CRh, complete remission with partial hematologic 
recovery; CrI, credible interval; OR, odds ratio; SOC, standard of care.
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Table 4. Summary of OS analysis with and without Bayesian augmentation and adjusted by inverse 
probability of treatment weighting (IPTW) – average treatment effect (ATE)  
Endpoint External SOC Blinatumomab study 
Non-Bayesian (65% power) HR 0.81 (95% CI 0.57–1.14); P = 0.20 
OS probability (95% CI)   
  3-month  79% (70%–89%) 83% (74%–93%) 
  6-month 52% (40%–68%) 59% (47%–74%) 
  9-month 39% (27%–57%) 47% (35%–64%) 
  12-month 32% (20%–50%) 40% (28%–57%) 
Bayesian augmentation (80% power) HR 0.77 (95% CrI 0.61–0.96); P = 0.031 
OS probability (95% CrI)   
  3-month 79% (77%–81%) 83% (82%–85%) 
  6-month 51% (47%–55%) 60% (57%–63%) 
  9-month 39% (34%–43%) 48% (44%–52%) 
  12-month 31% (26%–35%) 41% (37%–44%) 
CI, confidence interval; CrI, credible interval; HR, hazard ratio; OS, overall survival; SOC, standard of care.
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Figure Legend 
Figure 1. Survival Cox proportional hazards model estimates by treatment with (A) and without (B) 
Bayesian augmentation (80% power) and adjusted by inverse probability of treatment weighting (IPTW) 
– average treatment effect (ATE). Survival estimates are calculated given proportion of prior HSCT: 0.327 
for control and 0.4 for blinatumomab. CI, confidence interval; CrI, credible interval; HR, hazard ratio; 
HSCT, hematopoietic stem cell transplantation; SOC, standard of care. 
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Figure 1. 
 
